Clinical Trial: Focal Micro-boost Strategy in Patients With Intermediate- to High-risk Prostate Cancer (IR-HR PCa) Undergoing Hypofractionated Radiotherapy

U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07792993) titled 'Focal Micro-boost Strategy in Patients With Intermediate- to High-risk Prostate Cancer (IR-HR PCa) Undergoing Hypofractionated Radiotherapy' on Aug. 25.

Brief Summary: HYPO62 SPECIAL is a monocentric, prospective observational cohort study promoted by IFO-IRE/ISG, designed to evaluate a moderately hypofractionated radiotherapy strategy with focal micro-boost in patients with localized intermediate- or high-risk prostate cancer.

Definitive radiotherapy is an established treatment option for localized prostate cancer. Over recent decades, technical advances such as 3D conformal radiotherapy, IMRT, and multiparametric MRI have enabled...